Indication & Dosage |
|
|
Oral |
RHEUMATIC DISORDERS |
Adult:
100-200 mg/day in 2-4 divided doses. As modified-release formulation: Administer dose once daily. Max dose: 200 mg daily (combined oral and rectal forms). Elderly: >75 yr: Reduce initial dose. |
|
Oral |
OTHER PAINFUL CONDITIONS INCLUDING DYSMENORRHOEA |
Adult:
25-50 mg every 6-8 hr. Max: 200 mg daily (combined oral and rectal forms).
Elderly: >75 yr: Reduce initial dose. |
Max Dosage: 200 mg daily (combined oral and rectal forms). |
|
Intramuscular |
ACUTE EXACERBATIONS OF MUSCULOSKELETAL, JOINT, PERIARTICULAR AND SOFT-TISSUE DISORDERS |
Adult:
50-100 mg by deep inj into the gluteal muscle every 4 hr. Max: 200 mg in 24 hr for up to 3 days. |
Max Dosage: 200 mg in 24 hr for up to 3 days. |
|
Intramuscular |
PAIN FOLLOWING ORTHOPAEDIC SURGERY |
Adult:
50-100 mg by deep inj into the gluteal muscle every 4 hr. Max: 200 mg in 24 hr for up to 3 days. |
|
Rectal |
RHEUMATIC DISORDERS |
Adult:
100 mg at night or bid. Max: 200 mg daily (combined oral and rectal forms). |
|
Topical/Cutaneous |
LOCAL PAIN |
Adult:
Apply 2.5% gel bid-tid for up to 10 days. |
|
|
|
Administration |
Should be taken with food. (Preferably taken w/ or after meals.) |
|
|
Precautions |
Pregnancy, lactation. Renal or hepatic impairment. Elderly. Heart failure. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Acute interstitial nephritis, reversible decline in renal function; GI symptoms e.g. discomfort, nausea, diarrhoea; pain and tissue damage at inj site (IM). |
|
|
Adverse Drug Reactions |
Rarely, idiosyncrasy, anaphylaxis; very rarely GI haemorrhage. |
|
|
Interactions |
Risk of nephrotoxicity increased with ACE inhibitors, ciclosporin, tacrolimus or diuretics. Increased risk of hyperkalaemia with ACE inhibitors and potassium-sparing diuretics. Reduces effects of antihypertensives (e.g. ACE inhibitors, β-blockers). Increased risk of convulsions with quinolones. Increased risk of adverse effects with aspirin. Increased risk of GI bleeding and ulceration with corticosteroids, SSRIs, clopidogrel and ticlopidine. Increased risk of haematotoxicity with zidovudine. May alter the efficacy of mifepristone. Increased plasma levels with probenecid. |
|
|